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We investigated whether human articular chondrocytes can be labeled efficiently and for long-term with a green
fluorescent protein (GFP) lentivirus and whether the viral transduction would influence cell proliferation and
tissue-forming capacity. The method was then applied to track goat articular chondrocytes after autologous
implantation in cartilage defects. Expression of GFP in transduced chondrocytes was detected cytofluorimetrically
and immunohistochemically. Chondrogenic capacity of chondrocytes was assessed by Safranin-O staining, im-
munostaining for type II collagen, and glycosaminoglycan content. Human articular chondrocytes were efficiently
transduced with GFP lentivirus (73.4 0.5% at passage 1) andmaintained the expression of GFP up to 22 weeks of
in vitro culture after transduction. Upon implantation in nude mice, 12 weeks after transduction, the percentage of
labeled cells (73.6 3.3%) was similar to the initial one. Importantly, viral transduction of chondrocytes did not
affect the cell proliferation rate, chondrogenic differentiation, or tissue-forming capacity, either in vitro or in vivo.
Goat articular chondrocytes were also efficiently transduced with GFP lentivirus (78.3 3.2%) andmaintained the
expression of GFP in the reparative tissue after orthotopic implantation. This study demonstrates the feasibility of
efficient and relatively long-term labeling of human chondrocytes for co-culture on integration studies, and indi-
cates the potential of this stable labeling technique for tracking animal chondrocytes for in cartilage repair studies.
Introduction
Cartilage tissue engineering can provide functionalcartilaginous constructs that can be used for controlled
in vitro studies of chondrogenesis and potentially for in vivo
articular cartilage repair.1 For example, tissue-engineered
cartilage has been introduced as a model to investigate in-
teractions between different zonal populations of articular
chondrocytes,2 between primary and passaged chon-
drocytes,3 or between chondrocytes and other cell types,
including osteoblasts,2,4 human embryonic stem cells,5 and
synoviocytes.6 Engineered cartilaginous tissues have also
been used as in vitro model systems to study the integration
process of a cartilage graft with native cartilage7–9 or bone
tissue.10 In most of these coculture or integration studies,
however, some of the key mechanistic questions related to
the functional contribution of specific cell populations could
not be addressed, since chondrocytes were either unlabeled
or labeled with a membrane fluorescent dye,2 which is sub-
jected to natural fading with time.
Due to limited scientific evidence of the role of implanted
chondrocytes in a cartilage defect and of their extent of
participation in the repair process, chondrocyte labeling
would also be extremely important before cell grafting in
animal models. So far, only Dell’Accio et al.11 used a fluo-
rescent dye, PKH26, to label goat articular chondrocytes and
showed that implanted cells persisted for at least 14 weeks in
the defects and contributed to structural cartilage repair in a
goat model of autologous chondrocyte implantation. This
study represents an important milestone in the field, but the
method used for labeling was not ideal for long-term studies
because of the natural fading of PKH26 and the decrease in
intensity of labeling with cell divisions.11,12
With the perspective of performing controlled in vitro or
in vivo studies on the interaction between defined chon-
drocyte populations and other cell systems, a reliable tech-
nique for sustained chondrocyte labeling should be used.
Besides membrane fluorochromes,11,13 other methods for cell
tracking include the use of radioactive isotopes,14 Y chromo-
some–specific probes,15 or delivery of reporter genes. Among
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these, green fluorescent protein (GFP) is the most common
and popular since it can be easily and efficiently viewed by
blue fluorescent light excitation16 or by the use of antibodies.
Several methods for gene delivery have already been ap-
plied to chondrocytes for in vitro applications and in vivo
purposes,17,18 such as plasmids transfection19,20 and infec-
tion with adenovirus,21,22 retrovirus,22,23 and baculovirus.24
Among all viruses, lentiviral vectors based on human im-
munodeficiency virus offer many advantages, as they inte-
grate to the genome enabling long-term gene expression and
have the capacity to transduce both dividing and nondividing
cells.25,26
Transduction of articular chondrocytes by lentivirus or
retrovirus carrying GFP gene has previously been stud-
ied,22,23,27 but long-term gene expression and influence on
chondrocyte phenotype have not been systematically de-
scribed. Lu et al.23 showed that transduction of rat chon-
drocytes with GFP lentivirus allowed to initially label about
60% of the cells, while after 6 weeks only 21% of chon-
drocytes remained labeled. A high efficiency of labeling of
85% on osteoarthritic chondrocytes was achieved and
maintained over 15 weeks by Li et al.,22 but whether GFP
lentivirus transduction affected chondrocyte redifferentiation
was not described. Hirschmann investigated the efficiency of
retroviral gene transfer into articular chondrocytes of rabbit,
sheep, bovine, and human origin.27 The expression of the
GFP transgene remained stable for at least 4 weeks in vivo
when transduced cells were implanted into cartilage defects
in knee joints of rabbits. However, the influence of the
marking procedure on matrix production was only investi-
gated during chondrocyte expansion in monolayer.
Considering the limited density of cells in native cartilage
and the typical phase of chondrocyte expansion before im-
plantation or use in a variety of in vitro models, in this work
we aimed at determining (i) the effect of GFP lentivirus
transduction on human articular chondrocyte proliferation
and postexpansion redifferentiation capacity, and (ii) the
long-term in vitro or in vivo stability of GFP expression in
engineered cartilaginous tissues generated using lentiviral-
transduced human chondrocytes. The labeling of chon-
drocytes was followed by flow cytometry, fluorescence
microscopy, or immunohistochemistry against GFP. Chon-
drogenic redifferentiation of transduced cells was assessed in
different well-established models, including culture in mi-
cromass pellets28–30 orwithin hyaluronan-based scaffolds,31–33
as well as ectopic implantation in nude mice34–36 and system-
atically compared to the one of untransduced chondrocytes by
histological, immunohistochemical, and biochemical analyses.
Finally, to assess whether our labeling protocol could allow to
track chondrocytes after orthotopic implantation in animal
models, autologous GFP-transduced chondrocytes were also
implanted in articular defects created in goats, a species fre-
quently used for cartilage repair studies.11,37–39
Materials and Methods
Isolation and expansion of human
articular chondrocytes
Biopsies of human articular cartilage were collected post-
mortem from knee joints of two female donors of 37 and 77
years old (respectively donor A and B), and from three male
donors of 63, 70, and 76 years old (respectively donors C, D,
and E) without macroscopic signs of arthritis, with the ap-
proval of the local ethics committee and informed consent by
the relatives. Chondrocytes were isolated upon 22-h incu-
bation at 378C in 0.15% type II collagenase and resuspended
in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum (FBS), 100U=mL penicillin, and 100mg=mL
streptomycin (complete medium). Chondrocytes were plated
in tissue culture dishes at a density of 104 cells=cm2 and ex-
panded in complete medium supplemented with 1 ng=mL
transforming growth factor-b1 (TGF-b1) and 5ng=mL fibro-
blast growth factor-2. The use of these growth factors was
previously reported to increase chondrocyte proliferation
rate and redifferentiation capacity,28 and not to influence the
transduction efficiency with lentivirus.22 When cells were
subconfluent, they were detached by sequential treatment
with 0.3% type II collagenase and 0.05% trypsin=0.53mM
EDTA, and replated at 5103 cells=cm2. Cell proliferation
rate was defined as the total number of doublings during the
expansion phase divided by the time required for the ex-
pansion, and was expressed as doublings=day.40 In some
experiments, cells were frozen in presence of 20% FBS and
10% DMSO.
Lentivirus GFP production and titration
The plasmids pMD.2G (Addgene plasmid 12259),
pCMVDR8.91,41 and pWPXL-EGFP (Addgene plasmid
12257) were kindly provided by D. Trono (Geneva, CH,
Switzerland). High-titer GFP lentiviral supernatants were
generated by transient cotransfection of three plasmids in
293T cells using Fugene 6 (Roche, CH, Switzerland). About
293T cells (2.5106 cells) were transfected with 12 mg of
pWPXL-EGFP, 12 mg of pCMVDR8.91, and 5mg of pMD.2G.
Supernatants of transfected 293T cells were collected 2 and 3
days posttransfection, filtered through 0.45 mm pore size fil-
ters, and stored at 708C. The viral titer was determined on
HeLa cells infected with serial dilutions of each viral super-
natant in presence of protamine sulfate (5 mg=mL; Sigma,
St. Louis, MO) by flow cytometry analysis. The titer was
calculated according to the following formula: Transduction
Units (TU)=mL¼ (Percentage of GFP-positive cells=100)
(Number of cells infected)(Vector dilution factor), as de-
scribed previously.42 Viral titer typically ranged around
3.7106 TU=mL after 2 days and 2.0106 TU=mL after 3 days.
The cell lines 293T cells and HeLa cells were maintained in
Dulbecco’s modified Eagle’s medium containing 10% FBS,
100U=mL penicillin, and 100 mg=mL streptomycin.
Transduction of human articular chondrocytes
Freshly isolated articular chondrocytes (0.56106 cells)
were seeded in 56 cm2 dishes and transduced the following
day with 2.8106 or 5.6106 TU of GFP lentivirus (multi-
plicity of infection, MOI, of 5 or 10) in presence of protamine
sulfate 5mg=mL final. The percentage of GFP-positive cells
was assessed by flow cytometry, 3 days posttransduction to
determine the efficiency of transduction, and after the first
and second passages in culture, to follow the percentage of
GFP-expressing cells during expansion. Data acquisition
and analysis were performed using CellQuestPro software
(Becton Dickinson, Franklin Lakes, NJ). Transduced chon-
drocytes were expanded and cultured in pellets and 3D
scaffolds as described below, in parallel with untransduced
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cells, used as controls. For cytofluorimetry, cells were re-
trieved from pellets by sequential treatment with 0.3% type II
collagenase and 0.05% trypsin=0.53mM EDTA.
Culture of human articular chondrocytes
in micromass pellets
Second-passage cells, in aliquots of 5105, were centri-
fuged in polypropylene conical tubes (Sarstedt, Numbrecht,
Germany) to form spherical pellets, which were cultured for
2 weeks in 0.5mL of a chemically defined serum-free me-
dium containing 10 ng=mL TGF-b1 and 107 M dexametha-
sone, as previously described.28
Culture of human articular chondrocytes
on porous 3D scaffolds
HYAFF11 nonwoven meshes made of esterified hya-
luronic acid (Fidia Advanced Biopolymers, Abano Terme,
Italy) were cored as discs (6mm diameter, 1.5mm thick), and
placed on dishes coated with a thin film of 1% agarose.
Second-passage chondrocytes (5106=scaffold) were distrib-
uted on the top surface. Constructs were statically cultured
from 2 to 20 weeks in complete medium supplemented with
10 mg=mL insulin, 0.1mM ascorbic acid 2-phosphate, and
10 ng=mL TGF-b3, with culture medium replaced twice a
week. These supplements were previously shown to enhance
chondrogenesis of dedifferentiated human chondrocytes
during culture into HYAFF11 nonwoven meshes.35 Con-
structs (n¼ 4 per condition and time point) were either pre-
cultured for 2 weeks and further implanted in nude mice
as described below or were harvested at the time points 2,
4, 8, 12, 16, and 20 weeks, bisected, and analyzed by histol-
ogy, immunohistochemistry, biochemistry, and fluorescence
microscopy.
Ectopic implantation of human articular
chondrocyte constructs
Human articular chondrocyte–HYAFF11 constructs cul-
tured for 2 weeks (with control or transduced cells) were
implanted in the back of two nude mice (CD-1 nu=nu,
athymic, 6–8-week-old females) in a pocket between excised
muscle fascia and subcutaneous tissue. All animals in this
study were cared for and treated according to institutional
guidelines. Each mouse received four grafts, two generated
by control cells and two generated by transduced cells.
Constructs were harvested after 8 weeks and processed for
histological and immunohistochemical analyses and fluo-
rescence microscopy.
Generation and orthotopic implantation of autologous
goat articular chondrocytes constructs
Surgical procedures were performed following protocol
approval by the cantonal veterinary office (Amt fu¨r Land-
wirtschaft des Kantons Bern) using sterile techniques and
under general anesthesia. Anaesthetic inductionwas obtained
by intramuscular injection of xylazin (Vetoquinol, Ittigen,
Switzerland), followed by intravenous application of mid-
azolam (Roche Pharma, Basel, Switzerland), and the in-
traoperative anesthesia was maintained by isofluoran
inhalation. Postoperative antibiotic (Amoxycillin; Glaxo-
SmithKline AG, Mu¨nchenbuchsee, Switzerland) and anal-
getic (Flunixin; Biochema, Uzwil, Switzerland) therapy was
applied for another 3 days. In a first surgery, both posterior
legs of two skeletally adult female Saanen goats (older than 18
months) were laterally operated. To harvest the biopsies, four
circular defects of 6mm in diameter and 0.4–0.5mm in depth
were created in the cartilage of the trochlea groove using
a disposable biopsy punch (Stiefel, Offenbach am Main,
Germany). Chondrocytes isolated from the excised cartilage
were transduced atMOI of five using the protocols previously
described for human chondrocytes. Transduced chondrocytes
were then expanded for two passages in complete medium
supplemented with 5 ng=mL fibroblast growth factor-2.43 The
percentage of GFP-positive cells was quantified cytofluori-
metrically at the end of the second expansion as previously
described. Collagen type I=III membranes (Chondrogide;
Geistlich, Wolhusen, Switzerland) were cored as discs (6mm
diameter), and cells were statically seeded at a density of
2106 cells=scaffold on the porous side of the dry membrane,
the smooth side being rather impermeable to cells. Constructs
were then cultured for 2 weeks in a complete medium sup-
plemented with 10mg=mL insulin, 0.1mM ascorbic acid 2-
phosphate, and 10 ng=mL TGF-b3, with the culture medium
replaced twice a week. Four weeks after biopsy withdrawal,
in a second surgical intervention the biopsy sites in the
trochlea femoris were re-cored to a final size of 6mm diam-
eter2mm thickness and filled with the in vitro precultured
constructs, which were sutured to the surrounding cartilage
with four stitches. Goats were sacrificed 4 weeks postopera-
tively by injection of an overdose of phenobarbital, and
samples were harvested for the immunohistochemical detec-
tion of GFP-labeled chondrocytes.
Histological and immunohistochemical analyses
Cell pellets, engineered tissues, ectopic implants, or re-
parative tissues were fixed in 4% formalin, embedded in
paraffin, cross sectioned (5 mm thick for pellets and 7 mm
thick for engineered tissues and implants), and stained with
Safranin-O for sulfated glycosaminoglycans (GAG). In some
experiments, pellets or constructs were cryo-embedded; 7-
mm-thick sections were assessed for the expression of GFP by
direct observation using a fluorescent microscope (Axiophot;
Zeiss, Jena, Germany), using transmitted light images of the
same microscopic field to view all cells.
For immunohistochemical assessment of GFP expression,
sections were deparaffinized and incubated with 0.1% tryp-
sin for 20min at 378C and afterward with rabbit serum (di-
lution 1:20) for 10min. For detection of GFP in tissues
generated using human chondrocytes, sections were incu-
bated for 1 h with a goat polyclonal antibody against GFP
(dilution 1:200) (ab6673; Abcam, Cambridge, United King-
dom), followed by a secondary antibody, rabbit anti-goat
biotinylated (dilution 1:400) (E0466; Dako, Carpenteria, CA).
For detection of GFP in tissues generated using goat chon-
drocytes, sections were incubated for 1 h with a rabbit
polyclonal antibody against GFP (dilution 1:200) (ab290;
Abcam), followed by a secondary antibody, horse anti-rabbit
biotinylated (dilution 1:100) (BA-1400; Vector, Burlingame,
CA). The avidin–biotin complex coupled with alkaline
phosphatase (ABC=AP complex; Dako) was used for the
staining according to manufacturer’s instructions followed
by incubation with Fast Red substrate and Levamisole
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(Dako). The percentage of GFP-positive chondrocytes was
derived by manual counting of the number of cells positively
stained by Fast Red and of the number of total cells, which
were viewed by counterstaining with hematoxylin. The im-
plants were surrounded by a thin layer of fibroblastic cells,
which was not considered for analysis, since most likely
formed by mice cells. Four microscopic fields for each cross
section, corresponding to an average of 323 35 cells=field,
were assessed.
For collagen type II immunohistochemistry, sections were
processed using an antibody against type II collagen
(II-II6B3, Hybridoma Bank, University of Iowa) as previously
described.43
Biochemical analysis
Cell pellets and engineered tissues were digested with
proteinase K solution as previously described.44 GAG con-
tent was measured spectrophotometrically after reaction
with dimethylmethylene blue dye,45 with chondroitin sulfate
as a standard. The GAG content was normalized to the DNA
amount, which was measured using a CyQUANT cell pro-
liferation assay kit (Molecular Probes, Eugene, OR), with calf
thymus DNA as a standard.
Results and Discussion
Lentiviral transduction of chondrocytes
Human articular chondrocytes (donor B) were transduced
with the recombinant GFP lentivirus at MOI of 5 and 10. In a
preliminary experiment, the percentage of chondrocytes
positive for GFP as analysed by flow cytometry 6 days
posttransduction was not significantly higher when the
transduction was performed at MOI 10 as compared to MOI
5 (75.6% vs. 75.0%). For this reason, further experiments were
all conducted at MOI 5.
Three days posttransduction with GFP lentivirus, labeled
chondrocytes could be detected by fluorescence microscopy
FIG. 1. Representative pic-
tures of expanded chon-
drocytes untransduced
(control) (A, C) or after 3 days
of transduction with GFP
lentivirus (transduced) (B, D),
acquired under fluorescence
light (A, B) or under phase
contrast (C, D). (E) Flow
cytometry analysis of chon-
drocytes at passage 2. Black
line, control chondrocytes;
gray line, transduced chon-
drocytes. Scale bars: 100 mm.
GFP, green fluorescent
protein.
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(Fig. 1A, B). The percentage of GFP-positive cells 3 days
posttransduction was 71.1 2.6% as determined by cyto-
fluorimetry with cells from donors B, C, D, and E. At passage
2, the fraction of labeled cells could be quantified by a clear
positive peak by cytofluorimetry (Fig. 1E). The percentage of
GFP-positive cells after the first passage (corresponding to,
respectively, 2.8 and 3.9 doublings for cells from donors A
and B) was 73.6 1.4%, and remained essentially stable
(73.4 0.5%) after the second passage (corresponding to,
respectively, 7.2 and 7.5 doublings for cells from donors A
and B).
Cell proliferation rate and redifferentiation
capacity in pellets
The proliferation rate of chondrocytes, assessed until the
second passage of expansion, was only slightly variable us-
ing cells from the two donors, and was not significantly
different when cells were untreated (control) or transduced
with GFP lentivirus (Fig. 2). These results again confirm the
limited intradonor variability in the response of chon-
drocytes to GFP transduction.
The redifferentiation capacity of expanded chondrocytes
(donor A) was assessed in 3D micromass pellet cultures. The
intensity of staining for sulfated GAG (Safranin-O staining,
FIG. 2. Cell proliferation rate (as doublings=day) of chon-
drocytes isolated from cartilage biopsies of the two donors,
transduced with GFP lentivirus or untransduced (control)
and expanded for two passages.
FIG. 3. Chondrocyte redifferentiation in 3D pellets. Pellets generated from untransduced (control) (I), transduced (II), or
twice transduced (III) chondrocytes from donor A were stained by Safranin-O (A) or observed unstained under fluorescence
light (B) or transmitted light (C). The GAG=DNA ratio (mg=mg) of the pellets is indicated below each picture in (A). Scale bars:
100 mm. Color images available online at www.liebertonline.com=ten.
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Fig. 3A) was similar in pellets generated from control
chondrocytes as compared to GFP-transduced chondrocytes.
The GAG=DNA ratios were not significantly different in
pellets generated from control chondrocytes as compared to
GFP-transduced chondrocytes (Fig. 3A), consistently with
the Safranin-O staining. Observation of pellet cryosections
under fluorescent light demonstrated a positive signal when
chondrocytes were transduced with the GFP lentivirus (Fig.
3B). Our results are generally in agreement with previous
studies indicating that the expression of GFP protein does
not influence the chondrogenic differentiation of murine
mesenchymal progenitor cells.46,47
We next investigated the influence of cell freezing after
GFP transduction on the percentage of labeled chondrocytes
and on their redifferentiation capacity in pellets. The intro-
duction of a cell freezing step did not modify the percentage
FIG. 4. Analysis of con-
structs cultured for 4 weeks
and generated from un-
transduced (control) (I) or
transduced chondrocytes (II)
from donor A. Cross sections
were stained by Safranin-O
(A), immunostained for GFP
(B), or observed under fluo-
rescence light (C) or transmit-
ted light (D). Scale bars:
100 mm. Color images avail-
able online at www
.liebertonline.com=ten.
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of isolated fluorescent chondrocytes, as quantified by cyto-
fluorimetry (73.1% positive cells after the freezing step vs.
73.6% before cell freezing). Our findings are in line with
those by Li et al.,22 who reported that the expression of GFP
in transduced osteoarthritic chondrocytes was maintained
after freezing and re-culture.
Pellets generated from transduced chondrocytes with or
without freezing exhibited similar intensity of staining for
sulfated GAG (data not shown) and GAG=DNA ratios
(10.5 0.1 with freezing step vs. 11.2 0.6 without freezing
step). After 2 weeks in pellets, the fluorescence intensity of
transduced chondrocytes was comparable if a freezing step
was performed or not during previous cell expansion (data
not shown).
To possibly increase the percentage of GFP-labeled cells, a
second cycle of transduction was performed on already
transduced chondrocytes. This second cycle of transduction
increased the percentage of fluorescent chondrocytes from
73.6% to 85.6 1.5% at passage 1 as detected by cyto-
fluorimetry. This is consistent with Li et al.,22 reporting that
after two cycles of retroviral transduction the percentage of
labeled human chondrocytes increased from 85% to 96%.
Pellets generated from double-transduced chondrocytes ex-
hibited a similar intensity of staining for sulfated GAG as
well as similar GAG=DNA ratios as compared to those
generated from cells transduced only once (Fig. 3A). Ob-
servation of pellet cryosections under fluorescent light
qualitatively indicated a more homogenous green staining in
pellets generated from double-transduced chondrocytes as
compared to cells transduced only once (Fig. 3B). The per-
centages of single- or double-transduced chondrocytes en-
zymatically retrieved from pellets after 2 weeks culture and
still positive for GFP averaged, respectively, 62.5 2.3% or
75.9 4.6%, as assessed by cytofluorimetry.
Cell redifferentiation capacity in 3D scaffolds
As an independent model of chondrogenic differentiation
and tissue formation, untransduced (control) or transduced
chondrocytes (donor A), after 2 weeks of expansion, were
FIG. 5. Analysis of con-
structs implanted in nude
mice for 8 weeks and gener-
ated from untransduced (con-
trol) (I) or transduced
chondrocytes (II) from donor
A. Cross sections were stained
by Safranin-O (A), im-
munostained for type II colla-
gen (B), or immunostained for
GFP with hematoxylin coun-
terstain (C). Scale bar 100 mm.
Insets in (C) display higher-
magnification images of the
cells immunostained for GFP
and counterstained by
hematoxylin. Color images
available online at www
.liebertonline.com=ten.
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cultured in HYAFF11 scaffolds for up to additional 20
weeks. Engineered cartilaginous tissues continuously ma-
tured in vitro until 8 weeks, as indicated by Safranin-O
staining, but longer culture time led to progressive degra-
dation of the tissue, as typically occurs under static culture
conditions.48 After 4 weeks of culture, generated constructs
displayed faint staining for Safranin-O, which was of similar
intensity for control and transduced chondrocytes (Fig. 4A).
Immunohistochemistry for GFP protein indicated a strong
positive staining in constructs generated from transduced
cells (Fig. 4B), in correspondence both of elongated cells at
the construct periphery and of more rounded cells in the
central part of the tissue. After 8 weeks or longer culture
time, cells localized at the tissue periphery were still pre-
dominantly positively stained for GFP, whereas the construct
core was essentially necrotic, not allowing reliable assess-
ment of positivity for GFP staining (data not shown).
By fluorescence analysis of cryosections, HYAFF11 fibers
appeared unspecifically fluorescent in constructs generated
from control or transduced chondrocytes (Fig. 4C). The same
microscopic fields were thus observed also in light micros-
copy to distinguish fluorescent HYAFF11 fibers from fluo-
rescent cells (Fig. 4D). This analysis allowed to confirm that
only constructs generated using transduced chondrocytes
contained GFP-positive cells.
Cell redifferentiation capacity and tracking
after ectopic implantation in nude mice
Expanded, transduced, or untransduced chondrocytes
(donor A) were cultured in HYAFF11 scaffolds for 2 weeks
and further implanted subcutaneously in nude mice for 8
weeks. The chondrogenic redifferentiation capacity was as-
sessed via staining for sulfated GAG, which appeared to be
of strong and similar intensity in implants generated using
untransduced or transduced chondrocytes (Fig. 5A). A sim-
ilar intensity of immunostaining for collagen type II was
observed in implants generated from control or transduced
chondrocytes (Fig. 5B). Collagen type II positive staining was
detected in the same regions stained for sulfated GAG. GFP
expression was demonstrated by immunohistochemistry in
implants generated using transduced chondrocytes (Fig. 5C),
indicating that in vivo cells were still labeled and detectable.
Manual counting of cells positively stained for GFP and of all
cells with hematoxylin-stained nuclei was performed on his-
tological sections of implants generated using transduced
chondrocytes. Such counting demonstrated that 73.6 3.3%
of the cells in the implants were positive for GFP after
12 weeks of transduction, corresponding to a complete main-
tenance of labeling by the transduced cells. Fluorescence
analysis of cryosections of the implants confirmed the pres-
ence of GFP-expressing chondrocytes (data not shown).
Transduced chondrocytes implanted in nude mice did not
show an apparent reduction in the number of positive cells
after 12 weeks, while transduced chondrocytes cultured for
2 weeks in 3D pellets exhibited around 10% reduction of
GFP positivity. In the two experimental designs, we used
different culture systems (scaffolds vs. 3D pellets) as well as
distinct methodologies to determine the number of labelled
cells (direct counting after immunohistochemistry vs. cyto-
fluorimetry after enzymatic digestion of pellets). The meth-
odologies employed in this study could explain relative
variations observed in the number of GFP-positive chon-
drocytes.
FIG. 6. Analysis of the con-
structs implanted in goat car-
tilage defects for 4 weeks. (A)
GFP-labeled autologous
chondrocytes, cultured in
Chondrogide membranes for
2 weeks, were implanted into
goat trochlea defects. (B) After
4 weeks the defects were filled
with a smooth repair tissue.
(C, D) Immunohistochemical
staining demonstrated a large
amount of GFP-positive cells
in the reparative tissue. Color
images available online at
www.liebertonline.com=ten.
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Cell tracking after orthotopic implantation
in a goat model
The percentage of GFP-positive goat articular chon-
drocytes after the second passage was slightly higher after a
single transduction than that measured in human articular
chondrocyte cultures, averaging 78.3 3.2% as measured by
cytofluorimetry. This percentage is in the same range of that
reported by Ueblacker et al.49 and indicates that the protocol
used for labeling human chondrocytes is efficient also for the
transduction of chondrocytes from other species.
GFP-labeled chondrocytes were cultured in Chondrogide
membranes for 2 weeks and then implanted into defects
generated in the trochlea of goats (Fig. 6A). After 4 weeks,
visual observations showed an apparent good filling of the
defect with a relatively smooth surface (Fig. 6B). No in-
flammatory reactions, possibly related to scaffold degrada-
tion products, or blood vessel ingrowth were observed in the
repair tissue. Immunohistochemical analysis demonstrated a
large amount of GFP-positive cells (Fig. 6C, D) in the re-
parative tissue, indicating that the grafted chondrocytes re-
mained viable in the defect. Quantification of GFP-positive
cells from these sections (as percentage of total) appeared not
reliable, due to the possible infiltration of cells from other
compartments (e.g., the subchondral bone or synovial
membrane) in the grafted material, which could not be dis-
tinguished from nonlabeled implanted cells. Although in our
study only two goats have been used and a relative short
follow-up time was considered, the results represent a proof
of principle that the proposed GFP transduction method
would enable to track implanted chondrocytes in orthotopic
cartilage repair studies and possibly to evaluate the contri-
bution of grafted cells in the repair process.
Conclusions
We report that primary human articular chondrocytes
can be transduced by a GFP lentiviral vector at high effi-
ciency, with labeled cells detected up to 22 weeks after
transduction using in vitro 3D cultures, and up to 8 or 12
weeks in in vivo models, namely, orthotopic implantation in
goats and subcutaneous implantation in nude mice. Im-
portantly, chondrocyte transduction did not affect the cell
proliferation rate or the postexpansion redifferentiation ca-
pacity. The developed and validated technique could be
used as a tool to engineer labeled cartilage tissues, and in-
vestigate the interaction between chondrocytes and other
cell populations during crucial processes (e.g., migration,
differentiation, and integration) in in vitro systems or im-
munodeficient animal models. We additionally proved that
this method could be extended to the transduction of
chondrocytes from other species, thus allowing evaluating
the fate of implanted cells in orthotopic cartilage repair
studies in large animal models.
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